PRT-3645 is under clinical development by Prelude Therapeutics and currently in Phase I for Astrocytoma. According to GlobalData, Phase I drugs for Astrocytoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-3645’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-3645 is under development for the treatment of solid tumor including recurrent glioblastoma, melanoma, HER2-negative breast cancer, HER2 positive breast cancer, astrocytoma, malignant mesothelioma, HPV-negative HNSCC (including oral cavity, oropharynx, hypopharynx, and larynx), sarcoma and non-small cell lung cancer. The drug candidate acts by targeting CDK4 and CDK6. It is administered through oral route as capsules.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a biopharmaceutical company focused on discovering as well as developing small molecule therapies for the treatment of cancers with high unmet need. The company leverages its core competencies in medicinal chemistry and cancer biology coupled with agnostic approach target class and technology platform for drug discovery and creating new chemical entities. Pipeline candidates of the company include PRT543 for solid tumors and myeloid malignancies; PRT811 for GBM and CNS metastatic cancers; PRT1419 and PRT2527 for hematological malignancies; PRT-SCA2 for multiple genomically cancer and PRT-K4 for solid tumors. Prelude is headquartered in Wilmington, Delaware, the United States.
For a complete picture of PRT-3645’s drug-specific PTSR and LoA scores, buy the report here.